News
HQH
16.57
+0.62%
0.10
My #1 Income Strategy For 2025 (Safety, 14% Dividends On The Table)
NASDAQ · 3d ago
Weekly Report: what happened at HQH last week (1216-1220)?
Weekly Report · 3d ago
My 2024 Income Investor's Christmas Wish List
Seeking Alpha · 6d ago
Weekly Report: what happened at HQH last week (1209-1213)?
Weekly Report · 12/16 09:01
11 Closed-End Fund Buys In The Month Of November 2024
Seeking Alpha · 12/15 13:10
BMEZ: Remains Attractive With A Deep Discount
Seeking Alpha · 12/10 22:51
Weekly Report: what happened at HQH last week (1202-1206)?
Weekly Report · 12/09 09:01
The Two Trillion Dollar Question And The S&P 500's Cautionary Risk Premium
Seeking Alpha · 12/03 19:21
Weekly Report: what happened at HQH last week (1125-1129)?
Weekly Report · 12/02 09:01
2 Cyber Monday Picks I Am Buying Hand Over Fist
Seeking Alpha · 11/30 15:30
Weekly Report: what happened at HQH last week (1118-1122)?
Weekly Report · 11/25 09:01
HQH: Declines Bring Potential Opportunity
Seeking Alpha · 11/21 14:24
Weekly Report: what happened at HQH last week (1111-1115)?
Weekly Report · 11/18 09:01
abrdn Healthcare Investors declares $0.62 dividend
Seeking Alpha · 11/11 21:41
Weekly Report: what happened at HQH last week (1104-1108)?
Weekly Report · 11/11 09:01
Weekly Report: what happened at HQH last week (1028-1101)?
Weekly Report · 11/04 09:01
Worried About A Recession? Income Solutions With Yields Up To 13%
Seeking Alpha · 11/01 12:30
Weekly Report: what happened at HQH last week (1021-1025)?
Weekly Report · 10/28 09:01
Weekly Report: what happened at HQH last week (1014-1018)?
Weekly Report · 10/21 09:01
Weekly Report: what happened at HQH last week (1007-1011)?
Weekly Report · 10/14 09:01
More
Webull provides a variety of real-time HQH stock news. You can receive the latest news about abrdn Healthcare Investors through multiple platforms. This information may help you make smarter investment decisions.
About HQH
Tekla Life Sciences Investors (the Fund) is a diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in the United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, agriculture, and environmental management. The Fund invests primarily in securities of public and private companies, which have potential for above-average growth. The Fund may invest up to 20% of its net assets in securities of foreign issuers, located primarily in Western Europe, Canada and Japan, and securities of the United States issuers that are traded primarily in foreign markets. The Fund's investment advisor is Tekla Capital Management LLC.